New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a life-threatening respiratory illness that shares clinical similarities with autoimmune diseases, which some patients subsequently develop. We herein report a case of an older Japanese patient who presented with skin rash, relapsing progressive interstitial lung disease, and anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody seropositivity after COVID-19 infection. Although the patient was elderly, her symptoms improved with the administration of corticosteroids, tacrolimus, and intravenous cyclophosphamide, indicating that this combination may be a viable treatment option for anti-MDA5 antibody-positive pneumonia, which is a complication of COVID-19.
Related
- A comparison of clinical phenotype and outcomes in anti- melanoma differentiation-associated protein 5 dermatomyositis and anti-synthetase syndrome in a multiethnic cohort in Singapore
- Longitudinal interferon signatures are associated with disease flare in dermatomyositis
- Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report.
- Candidate molecular endotypes and dynamic risk prediction in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a systematic scoping review
- Differentiation of the acute changes in the inter-limb strength asymmetry profile of the lower limbs between winners and defeated athletes following a simulated karate bout
BibTeX
@article{nakanishi2026newonset,
title = {{New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19}},
author = {Yu Nakanishi and Hirofumi Watanabe and Mako Tsuyuki and Shinji Kakumoto and Masaaki Abe and Kosuke Hamai},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.5163-24},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_5163-24/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19
AU - Yu Nakanishi
AU - Hirofumi Watanabe
AU - Mako Tsuyuki
AU - Shinji Kakumoto
AU - Masaaki Abe
AU - Kosuke Hamai
PY - 2026
DA - 2026/07/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.5163-24
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_5163-24/_article
AB - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a life-threatening respiratory illness that shares clinical similarities with autoimmune diseases, which some patients subsequently develop. We herein report a case of an older Japanese patient who presented with skin rash, relapsing progressive interstitial lung disease, and anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody seropositivity after COVID-19 infection. Although the patient was elderly, her symptoms improved with the administration of corticosteroids, tacrolimus, and intravenous cyclophosphamide, indicating that this combination may be a viable treatment option for anti-MDA5 antibody-positive pneumonia, which is a complication of COVID-19.
SN - 1349-7235
SN - 0918-2918
ER -